One of the most powerful and multifaceted cytokines produced by immune cells are type I interferons (IFNs), the basal secretion of which contributes to the maintenance of immune homeostasis, while their activation-induced production is essential to effective immune responses. Although, each cell is capable of producing type I IFNs, plasmacytoid dendritic cells (pDCs) possess a unique ability to rapidly produce large amounts of them. Importantly, type I IFNs have a prominent role in the pathomechanism of various pDC-associated diseases. Deficiency in type I IFN production increases the risk of more severe viral infections and the development of certain allergic reactions, and supports tumor resistance; nevertheless, its overproduction promotes autoimmune reactions. Therefore, the tight regulation of type I IFN responses of pDCs is essential to maintain an adequate level of immune response without causing adverse effects. Here, our goal was to summarize those endogenous factors that can influence the type I IFN responses of pDCs, and thus might serve as possible therapeutic targets in pDC-associated diseases. Furthermore, we briefly discuss the current therapeutic approaches targeting the pDC-type I IFN axis in viral infections, cancer, autoimmunity, and allergy, together with their limitations defined by the Janus-faced nature of pDC-derived type I IFNs.

Cells utilize a diverse repertoire of cell surface and intracellular receptors to detect exogenous or endogenous danger signals and even the changes of their microenvironment. However, some cytosolic NOD-like receptors (NLR), including NLRX1, serve more functions than just being general pattern recognition receptors. The dynamic translocation between the cytosol and the mitochondria allows NLRX1 to interact with many molecules and thereby to control multiple cellular functions. As a regulatory NLR, NLRX1 fine-tunes inflammatory signaling cascades, regulates mitochondria-associated functions, and controls metabolism, autophagy and cell death. Nevertheless, literature data are inconsistent and often contradictory regarding its effects on individual cellular functions. One plausible explanation might be that the regulatory effects of NLRX1 are highly cell type specific and the features of NLRX1 mediated regulation might be determined by the unique functional activity or metabolic profile of the given cell type. Here we review the cell type specific actions of NLRX1 with a special focus on cells of the immune system. NLRX1 has already emerged as a potential therapeutic target in numerous immune-related diseases, thus we aim to highlight which regulatory properties of NLRX1 are manifested in disease-associated dominant immune cells that presumably offer promising therapeutic solutions to treat these disorders.

Antiviral type I interferons (IFN) produced in the early phase of viral infections effectively inhibit viral replication, prevent virus-mediated tissue damages and promote innate and adaptive immune responses that are all essential to the successful elimination of viruses. As professional type I IFN producing cells, plasmacytoid dendritic cells (pDC) have the ability to rapidly produce waste amounts of type I IFNs. Therefore, their low frequency, dysfunction or decreased capacity to produce type I IFNs might increase the risk of severe viral infections. In accordance with that, declined pDC numbers and delayed or inadequate type I IFN responses could be observed in patients with severe coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as compared to individuals with mild or no symptoms. Thus, besides chronic diseases, all those conditions, which negatively affect the antiviral IFN responses lengthen the list of risk factors for severe COVID-19. In the current review, we would like to briefly discuss the role and dysregulation of pDC/type I IFN axis in COVID-19, and introduce those type I IFN-dependent factors, which account for an increased risk of COVID-19 severity and thus are responsible for the different magnitude of individual immune responses to SARS-CoV-2.

Generally, a reciprocal antagonistic interaction exists between the antiviral type I interferon (IFN) and the antibacterial nucleotide-binding oligomerization domain (NOD)-like receptor pyrin domain containing 3 (NLRP3)-dependent IL-1β pathways that can significantly shape immune responses. Plasmacytoid dendritic cells (pDCs), as professional type I IFN-producing cells, are the major coordinators of antiviral immunity; however, their NLRP3-dependent IL-1β secretory pathway is poorly studied. Our aim was to determine the functional activity of the IL-1β pathway and its possible interaction with the type I IFN pathway in pDCs. We found that potent nuclear factor-kappa B (NF-κB) inducers promote higher levels of pro-IL-1β during priming compared to those activation signals, which mainly trigger interferon regulatory factor (IRF)-mediated type I IFN production. The generation of cleaved IL-1β requires certain secondary signals in pDCs and IFN-α or type I IFN-inducing viruses inhibit IL-1β production of pDCs, presumably by promoting the expression of various NLRP3 pathway inhibitors. In line with that, we detected significantly lower IL-1β production in pDCs of psoriasis patients with elevated IFN-α levels. Collectively, our results show that the NLRP3-dependent IL-1β secretory pathway is inducible in pDCs; however, it may only prevail under inflammatory conditions, in which the type I IFN pathway is not dominant.

Background/Objective: Accurate measurement of serum 25-hydroxyvitamin D (25OHD) is essential for the diagnosis and management of vitamin D deficiency. Although automated immunoassays are widely used in routine clinical practice, analytical variability between platforms may lead to inconsistent patient classification around clinically relevant decision thresholds. This study comprehensively compared three automated immunoassays (DiaSorin Liaison XL, Beckman Coulter DxI 9000, and Roche cobas e602) with a Vitamin D Standardization Certification Program (VDSCP)-traceable liquid chromatography–tandem mass spectrometry (LC-MS/MS) reference method. Methods: A total of 400 anonymized adult outpatient serum samples were prospectively collected and equally distributed across four predefined vitamin D concentration categories (<25, 25–49, 50–74, and ≥75 nmol/L). Samples were stored at −70 °C before simultaneous analysis on the three automated immunoassays and the reference LC-MS/MS platform. Method comparison included Deming regression, Bland–Altman analysis, and evaluation of diagnostic performance at clinically relevant thresholds (<25, <50, and <75 nmol/L). The effects of sample storage, vitamin D metabolites (C3-epi-25OHD₃ and 24,25-dihydroxyvitamin D₃), and external quality assessment (DEQAS) performance were also investigated. Results: Significant analytical differences were observed between all immunoassays and LC-MS/MS. Roche cobas e602 consistently overestimated 25OHD concentrations, resulting in reduced sensitivity but excellent specificity and positive predictive value across all clinical thresholds. Beckman Coulter demonstrated the highest sensitivity for detecting vitamin D deficiency but generated more false-positive classifications, particularly at the <75 nmol/L threshold. DiaSorin Liaison XL achieved the best overall balance between sensitivity, specificity, accuracy, and agreement with LC-MS/MS, with Cohen’s κ values ranging from 0.818 to 0.895 across decision thresholds. Higher concentrations of C3-epi-25OHD₃ and 24,25-dihydroxyvitamin D₃ were associated with greater positive bias in Roche measurements, while Beckman Coulter showed no significant metabolite-related interference, although the present correlation analyses could not establish independent analytical interference. DEQAS performance did not consistently reflect agreement with LC-MS/MS in patient samples. Conclusions: Despite ongoing international standardization efforts, clinically important differences remain among automated 25OHD immunoassays. Assay-specific analytical characteristics significantly influence patient classification around established decision thresholds. DiaSorin Liaison XL demonstrated the closest overall agreement with the reference LC-MS/MS method, whereas Beckman Coulter prioritized sensitivity and Roche specificity. These findings highlight the importance of method-aware interpretation of vitamin D results and support continued assay harmonization to improve comparability in routine clinical practice.